AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02058160
Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.
Trial: NCT02058160
Drug: Insulin glargine (HOE901)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Trial: NCT02058160
Drug: Metformin (Background Drug)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration
Trial: NCT00776867
Drug: perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
Trial: NCT03885388
Drug: MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: multicourse methotrexate chemotherapy
Trial: NCT02234180
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00559715
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg intravitreally monthly/on demand
Trial: NCT00559715
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg intravitreally monthly/on demand
Trial: NCT04796467
Drug: 68Ga-PSMA-617
RxNorm normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT04796467
Drug: 68Ga-P16-093
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT03697356
Drug: Lenalidomide, Bortezomib, Rituximab, Dexamethasone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~* Rituximab 375 mg/m2 intravenous on day 1~* Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~* Lenalidomide 15mg p.o on day 1-21~* Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months.
Trial: NCT01080586
Drug: Cyclosporine Capsules USP (Modified) 100 mg
RxNorm normalized name: cyclosporine Oral Capsule
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
Trial: NCT02910596
Drug: bethanechol chloride
RxNorm normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
Trial: NCT03468296
Drug: Intravitreal Aflibercept Injection 2mg
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
Trial: NCT00337558
Drug: Solifenacin succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00000516
Drug: enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00152516
Drug: levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
Trial: NCT03028155
Drug: Oxaliplatin: BSA-based HIPEC
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
Trial: NCT03028155
Drug: Oxaliplatin: Concentration-based HIPEC
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin: 230 mg/L
Trial: NCT03604549
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 10cc of saline will be infused via intrauterine catheter
Trial: NCT00630903
Drug: PUVA (8MOP + UVA) + IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
Trial: NCT00630903
Drug: PUVA (8-MOP + UVA)
RxNorm normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
Trial: NCT03039036
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
Trial: NCT03749915
Drug: Ametop
RxNorm normalized name: Solfametopirazina
DrugBank: Sulfametopyrazine (DB00664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine Hydrochloride Gel 4%
Trial: NCT00139932
Drug: formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04432207
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
Trial: NCT00678327
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00678327
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00678327
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00678327
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00678327
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00961415
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5mg/kg iv on day 1 of each 3-week cycle
Trial: NCT00961415
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 iv on day 1 of each 3-week cycle
Trial: NCT00961415
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg/m2 iv on day 1 of each 3-week cycle
Trial: NCT03722108
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Trial: NCT05303961
Drug: SA001 240mg + Rebamipide 200mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
Trial: NCT05303961
Drug: SA001 480mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
Trial: NCT05303961
Drug: SA001 710mg + Rebamipide 600mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
Trial: NCT05303961
Drug: SA001 360mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
Trial: NCT05303961
Drug: SA001 720mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
Trial: NCT01822340
Drug: Genotropin
RxNorm normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily Genotropin
Trial: NCT01493596
Drug: CPP-115
RxNorm normalized name: CPP-115 free base
DrugBank: CPP-115 free base (DB17919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
Trial: NCT05072821
Drug: Botulinum Toxin Type A Injection [Botox]
RxNorm normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
Trial: NCT05072821
Drug: 0.9% Sodium Chloride Injection
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
Trial: NCT00535028
Drug: AER 001
DrugBank: AER001 (DB05078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AER 001 25 mgs s.c. once daily for 28 days
Trial: NCT01030094
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
Trial: NCT01030094
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
Trial: NCT01030094
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
Trial: NCT02412722
Drug: Sapanisertib
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib capsules
Trial: NCT02412722
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel injection
Trial: NCT02941523
Drug: NOX66
RxNorm normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NOX66 administration
Trial: NCT02941523
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administration
Trial: NCT02539368
Drug: Remicade
RxNorm normalized name: Remicade
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab
Trial: NCT02730455
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01198873
Drug: Dronedarone
RxNorm normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)
Trial: NCT02004067
Drug: Restasis
RxNorm normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
Trial: NCT01407484
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
Trial: NCT04006873
Drug: Tezacaftor/Ivacaftor + Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As per description in arms.
Trial: NCT03993639
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of SC administration
Trial: NCT02339740
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02339740
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02339740
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT02339740
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02339740
Drug: Mitoxantrone Hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00645944
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
Trial: NCT00168727
Drug: ibritumomab tiuxetan (Zevalin®)
RxNorm normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02260258
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular Blockade
Trial: NCT00232479
Drug: trastuzumab, docetaxel and carboplatin in dose dense regimen
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
Trial: NCT03740958
Drug: rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous throbolysis with 0.9mg/kg rtPA
Trial: NCT03740958
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
Trial: NCT00528333
Drug: Lintuzumab (SGN-33)
RxNorm normalized name: Lintuzumab
DrugBank: Lintuzumab (DB14877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
Trial: NCT00528333
Drug: Low dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
Trial: NCT02049957
Drug: Sapanisertib
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapnisertib capsules
Trial: NCT02049957
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant IM injection.
Trial: NCT02049957
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane tablets.
Trial: NCT00026416
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03693833
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) tablets of 10mg each
Trial: NCT02875028
Drug: Vorapaxar
RxNorm normalized name: Vorapaxar
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
Trial: NCT03559725
Drug: Nicotine gum (C)
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine gum
Trial: NCT03944109
Drug: SHR-1209
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Trial: NCT00003822
Drug: apomine
RxNorm normalized name: Apomine
DrugBank: Apomine (DB12276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01436643
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
Trial: NCT01436643
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
Trial: NCT01436643
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.